Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis (0812-008)

A Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of MK0812 in Rheumatoid Arthritis Patients

To demonstrate the clinical effectiveness of MK0812 in the treatment of Arthritis.

Inclusion Criteria:

• Patient has had diagnosis of RA made at least 6 months prior to study start and was greater than 16 years of age when diagnosed
• Patient has active RA with a minimum level of disease activity including at least 10 swollen joints and 10 tender or painful joints
• Excepting rheumatoid arthritis, patient is judged to be in otherwise general good health based on medical history, physical examination, and routine laboratory tests

Exclusion Criteria:

• Patient is mentally or legally incapacitated, has significant emotional problems at the time of the study, or has a history of psychosis
• Patient has a history of any clinically significant disease of the cardiovascular, hepatic, neurological, renal, genitourinary, or hematologic systems or uncontrolled blood pressure
• Female patient is pregnant or breast-feeding